Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, cold rubs, eye drops, troches, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, it offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. The company provides its products in gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynaecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for JBCHEPHARM
Revenue projections for JBCHEPHARM

JBCHEPHARM's revenue projections indicate a decrease from last year's performance, which could lead to investor caution. A fall in revenue is likely to negatively impact the company's profitability, causing concern for shareholders who may view this as a signal of declining financial health.

Financial Ratios:

currentRatio 4.92100
forwardPE 30.04436
debtToEquity 0.08600
earningsGrowth -0.31100
revenueGrowth -0.02400
grossMargins 0.69195
operatingMargins 0.21908
trailingEps 44.35000
forwardEps 72.89222

With a current ratio 4.921, J. B. Chemicals & Pharmaceuticals Limited demonstrates the ability to service its short-term debt without difficulty. The company's strong cash reserves and current assets ensure that it can meet its liabilities, reflecting financial stability and healthy liquidity.
With both earnings and revenue growth in low territory, JBCHEPHARM is likely to see shrinking profits. This signals a possible downturn in the company's financial health and may raise concerns about its future profitability.
JBCHEPHARM's positive gross and operating margins indicate healthy profitability. These margins reflect the company's ability to generate income efficiently from its operations, signaling strong financial performance and effective cost management.
JBCHEPHARM's forward EPS surpassing its trailing EPS signals projected growth in profitability, with the company expected to perform better this year. This forecast suggests that JBCHEPHARM's earnings will improve compared to the previous financial year, highlighting optimism in its financial outlook.

Price projections:

Price projections for JBCHEPHARM
Price projections for JBCHEPHARM

J. B. Chemicals & Pharmaceuticals Limited's price has consistently been situated near the lower end of expected values. This ongoing trend may reflect investor skepticism about the company's growth potential and overall performance.

Insider Transactions:

Insider Transactions for JBCHEPHARM
Insider Transactions for JBCHEPHARM


55 transactions were made to sell JBCHEPHARM shares, with market price of 1720.2718195134944.JBCHEPHARM saw 3 buy transactions, with market price of 1875.4333089192708.There is no clear trend from the insider transactions, providing limited insights into whether these actions reflect growth or decline.

Recommendation changes over time:

Recommendations trend for JBCHEPHARM
Recommendations trend for JBCHEPHARM


Analysts have maintained a buy bias for JBCHEPHARM, which could prompt investors to consider the stock as a viable investment. With this positive outlook, JBCHEPHARM is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.